InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,712.69
(
-0.28%
)
US TECH 100
19,440.40
(
0.00%
)
Dow Jones
41,794.60
(
-0.61%
)
Brent Oil
75.07
(
-0.07%
)
Bitcoin
68,857.73
(
1.53%
)
Post# of 253527
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: biomaven0 post# 210368

Saturday, 04/01/2017 11:21:05 PM

Saturday, April 01, 2017 11:21:05 PM

Post# of 253527
>>The fusions and some of the driver mutations seem to out-compete other clones and crowd out other pathways and so they tend to be mutually exclusive with other mutations and upregulated pathways.

No sooner did I post this than I saw this LOXO PR for a glioblastoma that had only part of the tumor fusion-driven:

http://finance.yahoo.com/news/loxo-oncology-announces-proof-concept-203000489.html

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up